眼精疲労に対するアデノシン三リン酸二ナトリウム（ATP-2Na）の臨床評価

Clinical evaluation of peroral adenosine triphosphate disodium hydrate（ATP-2Na）for asthenopia

要約　目的：眼精疲労に対する三リン酸二ナトリウム（ATP-2Na）内服の効果の報告。

対象と方法：眼精疲労を訴える患者40例を対象とした。男性5例，女性35例で，年齢は25〜87歳，平均62.5歳である。全例に，ATP-2Na 200〜300mg/日を3か月間投与し，投与前，1か月後，3か月後の眼精疲労とそれに伴う全身症状と精神症状を調査した。効果の判定には，visual analog scale（VAS）を用いた。

結果：1か月間服用を継続した31例では，眼精疲労，全身症状，精神症状とも有意に改善した（p＜0.005）。さらに継続して3か月間服用した26例でも，同様に有意に改善した（p＜0.005）。服用1か月時に来院した33例で，副作用として下痢2例，悪心1例があり，服用中止で副作用は消失した。

結論：ATP-2Naの内服で，比較的早期に眼精疲労が軽減し，これに伴う全身症状と精神症状にも効果のある可能性がある。

Abstract　Purpose: To report the effect and safety of peroral administration of adenosine triphosphate disodium hydrate（ATP-2Na）for asthenopia.

Cases and Method: This clinical study was made on 40 outpatients who complained of asthenopia. The series comprised 5 males and 35 females. The age ranged from 25 to 87 years, average 62.5 years. Each patient received ATP-2Na at the daily dosis of 200 to 300 mg. A questionnaire was used to evaluate the state of asthenopia and the other systemic and mental fatigue. The findings were analyzed using visual analog scale（VAS）.

Results: A total of 31 cases responded to the questionnaire after treatment for one month, reporting significant improvements in asthenopia as well as systemic and mental fatigue（p＜0.005）. In 26 cases who continued the treatment for 3 months, asthenopia as well as systemic and mental fatigue improved significantly（p＜0.005）. Side effects were reported in 3 out of 33 cases who continued the treatment for one month, including diarrhea in 2 cases and nausea in one. The side effects disappeared after discontinuation.

Conclusion: The present study shows that peroral ATP-2Na may induce early improvement of asthenopia as well as systemic and mental fatigue.